These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 10734296)
1. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296 [TBL] [Abstract][Full Text] [Related]
2. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280 [TBL] [Abstract][Full Text] [Related]
3. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. Claret EJ; Alyea EP; Orsini E; Pickett CC; Collins H; Wang Y; Neuberg D; Soiffer RJ; Ritz J J Clin Invest; 1997 Aug; 100(4):855-66. PubMed ID: 9259585 [TBL] [Abstract][Full Text] [Related]
4. Changes in the T-cell receptor V beta gene repertoire after allogeneic hematopoietic stem cell transplantation. Liu QF; Li YQ; Yang D; Zhang Y; Yang LJ; Chen SH; Sun J; Liu XL; Zhou SY Chin Med J (Engl); 2004 Mar; 117(3):413-8. PubMed ID: 15043783 [TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218 [TBL] [Abstract][Full Text] [Related]
6. Longitudinal analysis of T-cell receptor variable beta chain repertoire in patients with acute graft-versus-host disease after allogeneic stem cell transplantation. Liu C; He M; Rooney B; Kepler TB; Chao NJ Biol Blood Marrow Transplant; 2006 Mar; 12(3):335-45. PubMed ID: 16503503 [TBL] [Abstract][Full Text] [Related]
7. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267 [TBL] [Abstract][Full Text] [Related]
8. [Molecular characteristics of T-cell receptor of clonal expansion of T lymphocytes in leukemia patients after haploidentical bone marrow transplantation]. Fu YW; Wu DP; Feng YF; Chang WR; Zhu ZL; Zhu P Ai Zheng; 2007 Mar; 26(3):236-40. PubMed ID: 17355783 [TBL] [Abstract][Full Text] [Related]
9. [The molecular characteristics of T-cell immune reconstitution in leukemia patients after allogeneic hematopoietic stem cell transplantation]. Fu YW; Wu DP; Sun AN; Feng YF; Chang WR; Zhu ZL; Zhu P Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):312-7. PubMed ID: 17877159 [TBL] [Abstract][Full Text] [Related]
10. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403 [TBL] [Abstract][Full Text] [Related]
11. Distinct TCRAV and TCRBV repertoire and CDR3 sequence of T lymphocytes clonally expanded in blood and GVHD lesions after human allogeneic bone marrow transplantation. Hirokawa M; Matsutani T; Saitoh H; Ichikawa Y; Kawabata Y; Horiuchi T; Kitabayashi A; Yoshioka T; Tsuruta Y; Suzuki R; Miura AB; Sawada K Bone Marrow Transplant; 2002 Dec; 30(12):915-23. PubMed ID: 12476285 [TBL] [Abstract][Full Text] [Related]
12. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270 [TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
14. Efficient identification of T-cell clones associated with graft-versus-host disease in target tissue allows for subsequent detection in peripheral blood. Beck RC; Wlodarski M; Gondek L; Theil KS; Tuthill RJ; Sobeck R; Bolwell B; Maciejewski JP Br J Haematol; 2005 May; 129(3):411-9. PubMed ID: 15842666 [TBL] [Abstract][Full Text] [Related]
15. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease. Jiang YZ; Mavroudis DA; Dermime S; Molldrem J; Hensel NF; Barrett AJ Bone Marrow Transplant; 1997 May; 19(9):899-903. PubMed ID: 9156263 [TBL] [Abstract][Full Text] [Related]
16. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Xia G; Truitt RL; Johnson BD Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723 [TBL] [Abstract][Full Text] [Related]
17. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. Johnson BD; Becker EE; LaBelle JL; Truitt RL J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039 [TBL] [Abstract][Full Text] [Related]
18. [Allogeneic bone marrow transplantation for refractory multiple myeloma: presence of a graft-versus-myeloma effect]. Nawa Y; Noguchi T; Kojima K; Hara M Rinsho Ketsueki; 2001 Jun; 42(6):481-7. PubMed ID: 11505527 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions. Fuchs EJ; Seber A; Altomonte V; Braine HG; Humphrey RL; Jones RJ; Noga SJ; Schepers K; Wright SK; Vogelsang GB Bone Marrow Transplant; 1998 Aug; 22(3):303-5. PubMed ID: 9720749 [TBL] [Abstract][Full Text] [Related]
20. The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions. Mutis T; Aarts-Riemens T; Verdonck LF Haematologica; 2005 Oct; 90(10):1389-95. PubMed ID: 16219576 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]